{
  "docId": "019dd923-5efe-75c0-8dfe-c33214992e60",
  "docSlug": "e4e961afe28a39dc",
  "documentTitle": "2026 Investor Deck",
  "authorId": "JPMorgan-IR",
  "authorName": "Summit Therapeutics",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 13,
  "pageCount": 15,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "financial_analysis",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide highlights a strong liquidity position with significant cash and zero debt.",
  "elementsJson": [
    "headline_text",
    "big_number"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5efe-75c0-8dfe-c33214992e60/13",
  "deckHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60",
  "deckJsonHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60.json",
  "deckAnchorHref": "/decks/019dd923-5efe-75c0-8dfe-c33214992e60#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.66,
        "x": 0.326,
        "y": 0.945
      },
      "kind": "disclaimer",
      "text": "Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e277090c-5e66-41a9-8f46-c874cc8dff42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.181,
        "w": 0.506,
        "x": 0.247,
        "y": 0.535
      },
      "kind": "metric",
      "text": "$0 No Debt as of 12/31/2025",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39153277-739f-4cc0-b581-621a12a70ec6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.181,
        "w": 0.506,
        "x": 0.247,
        "y": 0.225
      },
      "kind": "metric",
      "text": "~$710M Unaudited Cash as of 12/31/2025",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5772467b-35a2-4c70-a159-b1787ea0abb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Cash and Debt: $710M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-7321-74b0-ac7f-beea70cd3de8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Strong Balance Sheet to Kick Off 2026",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c69774e-38a4-4a6d-93af-b6f9eeccc2d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 13,
      "beatId": "30f96b06-3487-46b3-a5f5-2bcb808d5b16",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "Slide 13 shows Strong Balance Sheet to Kick Off 2026",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "79e0c4c9-6f51-444c-a54b-594ca0500180",
      "evidence": "The deck implies the cost of inaction through its emphasis on Ivonescimab's development progress and potential",
      "position": 0,
      "objective": "Highlighting the importance of timely progress in biopharma development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}